However, in ER-negative cancers (ERneg), the Yap1high status consistently had a lower survival rate in human patients compared with the Yap1low status (80/199 vs. 159/255, p< 0.05) (Figure 6D, Table 2), suggesting that Yap1 may be a potential driver gene for treating this breast cancer subtype. This evidence concerns the gene YAP1 and breast carcinoma.